TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04459273

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 FAPi-46
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: Given IV
Study: NCT03897751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABT12 Multi-Purpose Solution
Description: Contact lens cleaning and disinfecting solution

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: COMPLETE Multi-Purpose Solution
Description: Contact lens cleaning and disinfecting solution

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensitive Eyes® Rewetting Drops
Description: For use as needed during the study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sensitive Eyes® Rewetting Drops
Description: For use as needed during the study.
Study: NCT02111278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Patients will receive 4 weeks of physical therapy with 2 visits per week. The treating physical therapist is blinded to group allocation. The treating physical therapist will prescribe exercises based on patient presentation. Therapy visits last approximately 45-60 minutes depending of patient ability to perform exercises. The treating physical therapist will perform no mobilizations or manipulations on the patient.
Study: NCT02843997

Intervention type: GENETIC
Group type: OTHER
Intervention: Endophenotype and sequencing
Description: Draw an endophenotype and genetic study
Study: NCT01757145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: From day +1, start eltrombopag 100 mg/d. If primary end point not reached on day +14, then from day +15 - 150 mg/d.~If primary end point not reached on day +28 then from day +29 - 200 mg/d. If primary end point not reached on day +42 then from day +43 and on - 300 mg/d maximal dose).~If present dose not tolerated, return to last tolerated dose. Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets. In case of decline of platelet count \< 30,000/microliter within 15 days from eltrombopag discontinuation, it will be resumed for additional 4 weeks. After 4 weeks we will re-attempt to hold the drug (if the threshold of platelet count \>50,000/microliter will be reached again).
Study: NCT03997227

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae Block
Description: After anesthesia and surgical procedures, a bilateral ESP block with ultrasound guidance will be applied from the T10 level at the middle line 3 cm lateral. Prior to the block, with povidone iodine, the T10 transverse protrusion will be determined by using linear ultrasound probe. The local anesthetic will be applied between the transverse projection and the erector spina muscle with the help of an isolated needle designed for peripheral block operations. Without local anesthesia, the location of the needle with saline will be confirmed by hydrodissection. After confirming the location of the needle, 20 ml of LA and saline mixture will be applied and the same procedure will be repeated in the control. A total of 40 ml of LA, 20 ml of bupivacaine 0.5%, 10 ml of lidocaine 2%, 10 ml of saline will be composed of saline.
Study: NCT03430713

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measure of tooth color
Description: Evaluation of agreement about measure of tooth color between clinicians using two dental shade guides and two spectrophotometers in the determination of the color of maxilary central incisors and canines.
Study: NCT03276169

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure
Description: Left atrial appendage closure is performed using a single endocardial plug devices guided by fluoroscopic guidance and transesophageal echocardiography
Study: NCT01710657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide 50 mg
Description: * Active Substance: Lacosamide~* Pharmaceutical Form: Film-coated tablet~* Concentration: 50 mg~* Route of Administration: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide 50 mg
Description: * Active Substance: Lacosamide~* Pharmaceutical Form: Film-coated tablet~* Concentration: 50 mg~* Route of Administration: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide 100 mg
Description: * Active Substance: Lacosamide~* Pharmaceutical Form: Film-coated tablet~* Concentration: 100 mg~* Route of Administration: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide 100 mg
Description: * Active Substance: Lacosamide~* Pharmaceutical Form: Film-coated tablet~* Concentration: 100 mg~* Route of Administration: Oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral Placebo tablets twice daily for 16 weeks.
Study: NCT02231749

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Study: NCT00038675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate (Gleevec)
Description: Imatinib mesylate 400 mg orally daily, and in HES patients start with imatinib mesylate 100 mg orally daily
Study: NCT00184600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart
Description: Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, once or twice daily plus option for insulin aspart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, once or twice daily plus option for insulin aspart
Study: NCT03276169

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radiofrequency ablation
Description: Each patient with persistent AF receives circumferential pulmonary vein isolation under the 3D electro-anatomical mapping system , and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LAAC combined with radiofrequency ablation group
Description: Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
Study: NCT03072160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg will be administered as a 30 minute intravenous (IV) infusion every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg will be administered as a 30 minute intravenous (IV) infusion every 3 weeks.
Study: NCT01091571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Description: Oral treatment with dipyridamole 200 mg twice daily during seven consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily during seven consecutive days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LPS
Description: The LPS derived from E. coli O:113 2ng/kg iv will be injected in 1 minute at a dosage of 2 ng/kg body weight.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: LPS
Description: The LPS derived from E. coli O:113 2ng/kg iv will be injected in 1 minute at a dosage of 2 ng/kg body weight.
Study: NCT01577238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% SPL7013 Gel
Description: Vaginal gel, daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaginal gel, daily for 7 days
Study: NCT03554044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Given IT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Given IV
Study: NCT00184600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, twice daily plus option for insulin detemir
Study: NCT00006365

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 125

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT03363503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone Capsair®
Description: Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Capsair® for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol/Fluticasone Diskus®
Description: Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus® for 8 weeks
Study: NCT04697017

Intervention type: OTHER
Group type: OTHER
Intervention: The contribution of genetics to dental caries, oral habits and occlusal traits in children of multiple births
Description: The contribution of genetics to dental caries, oral habits and occlusal traits in children of multiple births

Intervention type: OTHER
Group type: OTHER
Intervention: The contribution of genetics to dental caries, oral habits and occlusal traits in children of multiple births
Description: The contribution of genetics to dental caries, oral habits and occlusal traits in children of multiple births
Study: NCT00322621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Study: NCT01704612

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: ropivacaine
Description: patients received 20 mL ropivacaine 5 mg/mL on subgluteal nerve

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: patients received 20 mL ropivacaine 5 mg/mL on subgluteal nerve
Study: NCT04272112

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: IPS e.max CAD, Ivoclar Vivadent
Description: Type: monolithic lithium-disilicate glass ceramic

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: IPS e.max CAD, Ivoclar Vivadent
Description: Type: monolithic lithium-disilicate glass ceramic

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: BruxZir, Glidewell
Description: Type: high translucent zirconia

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: BruxZir, Glidewell
Description: Type: high translucent zirconia

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: BruxZir*, Glidewell
Description: Type: high translucent zirconia with a mini-veneer of porcelain

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: BruxZir*, Glidewell
Description: Type: high translucent zirconia with a mini-veneer of porcelain
Study: NCT03409978

Intervention type: DEVICE
Intervention: in-Motion app
Description: mobile phone application for recording fidgety movements at home
Study: NCT02294760

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subsensory
Description: The stimulation is set to 90% of the sensory threshold.
Study: NCT05281822

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The stress management training
Description: The women in the experimental group were provided with stress management training to help cope with stress conditions how to use positive coping in conditions in case of stress and tension.
Study: NCT02698982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Depth of anesthesia monitoring (BIS, Covidien USA) and Continus non invasive blood pressure monitoring (Clearsight, Edwards LifeScience, USA)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: moderate risk surgery

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: moderate risk surgery
Study: NCT04608253

Intervention type: DIAGNOSTIC_TEST
Intervention: 11C-choline PET/CT
Description: 11C-choline PET/CT
Study: NCT03314298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone anastrozole
Description: subcutaneous testosterone and anastrozole
Study: NCT03923465

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure: Periodontal surgery with entire papilla preservation (EPP) technique
Description: After local anesthesia injection an modified flap is designed according to minimally invasive microsurgical techniques. After flap elevation, careful removal of granulation tissues from the periodontal defects is performed. Scaling and root planing of the involved dental roots is ensured and finally suture is placed.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Procedure: Periodontal surgery with entire papilla preservation (EPP) technique
Description: After local anesthesia injection an modified flap is designed according to minimally invasive microsurgical techniques. After flap elevation, careful removal of granulation tissues from the periodontal defects is performed. Scaling and root planing of the involved dental roots is ensured and finally suture is placed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMD application
Description: Application of Pref-Gel for 2 minutes and then the application of Enamel Matrix Derivatives (EMD) on the surgically exposed root surface.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone substitutes application
Description: Following the application of EMD, filling the bone defect with bone substitutes.
Study: NCT04334174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Brentuximab Vedotin will be dosed at 1.8 milligram (mg) per (/) kilogram (Kg) of participants body weight will be infused intravenously every three weeks for up to ten infusions.
Study: NCT02023853

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasonic
Study: NCT02294760

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subsensory
Description: The stimulation is set to 90% of the sensory threshold.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OFF
Description: The stimulation is turned OFF.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OFF
Description: The stimulation is turned OFF.
Study: NCT01038869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelaic acid
Description: Apply sparingly to the face twice a day (morning and night). Massage gently into the skin until vanishing. Approximately 0.5g (2.5cm strip) is sufficient for the entire facial area.
Study: NCT00021073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study: NCT00977457

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA methylation analysis
Description: Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RNA analysis
Description: Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
Study: NCT03554044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study: NCT03118947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth, OR Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
Study: NCT01261819

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cystoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cystoscopy
Study: NCT02502760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise Program
Description: Physical exercises personalized by a kinesiologist consisting of walking or stationary bike and elastic band exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise Program
Description: Physical exercises personalized by a kinesiologist consisting of walking or stationary bike and elastic band exercises.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein Isolate Powder
Description: Nutritional counselling is given to patients to ensure their daily proteins and energy requirements are met. Whey Protein Isolate Powder (Immunocal) is provided.~Immunocal1.5g/kg PO (by mouth) per day separated in 2 daily doses

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein Isolate Powder
Description: Nutritional counselling is given to patients to ensure their daily proteins and energy requirements are met. Whey Protein Isolate Powder (Immunocal) is provided.~Immunocal1.5g/kg PO (by mouth) per day separated in 2 daily doses

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Techniques
Description: Relaxation techniques consisting of breathing exercises and using a relaxation CD.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Techniques
Description: Relaxation techniques consisting of breathing exercises and using a relaxation CD.
Study: NCT00977457

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Description: Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
Study: NCT04121845

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Sinus Reducer device
Description: Coronary sinus reducer device (Neovasc, Richomnd, Canada) implantation in the coronary sinus. The procedure is performed in the cardiac catheterization laboratory through right internal jugular vein.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Puncture of the right internal jugular vein and simulation of the CSR implantation procedure.
Study: NCT01743833

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic High Velocity, Low Amplitude Thrust Maneuver (HVLATM)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic High Velocity, Low Amplitude Thrust Maneuver (HVLATM)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scapular High Velocity, Low Amplitude Thrust Maneuver

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scapular High Velocity, Low Amplitude Thrust Maneuver
Study: NCT02611401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: The MBI is based on MBSR protocol but in order to maximize the clinical utility in people with MS suffering from depressive symptoms, we will tailor mindfulness intervention on the needs of this specific population. We will apply a modified MBSR protocol integrated with techniques from Sensorimotor Psychotherapy.~The MBI comprises an 8-week group program. Participants will took part in a 3 hour single weekly sessions, and there will be also an additional all-day session of 7 hours. Each session will cover specific exercises and topics within the context of mindfulness practice and training. Participants will be required to carry out daily 45-min homework assignments, which consist on mindfulness exercises and mindfulness applications in everyday life.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: The control group is designed to control for the nonspecific elements of the MBI treatment. It will be based on a psycho-educational framework and will include some relaxation techniques. In each session is discussed a MS-related topic. Relaxation and gentle stretching exercises will be proposed at the end of each session. Homework and the material (photocopies, slides, etc.) discussed in group sessions is left to each participant to encourage participants to practice exercises between sessions.~This intervention will follow the same structure and weekly format of the MBI intervention. The only difference will be the absence of an all-day session.
Study: NCT00553462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02958943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On-screen electronic alert
Description: On-screen notification regarding the patient's increased risk of stroke in AF and the lack of an active order for anticoagulation. Providers may then 1) access a template of FDA-approved anticoagulation regimens for stroke prevention in AF, 2) follow a link to evidence based clinical practice guidelines, or 3) proceed onto order entry after providing an explanation for why anticoagulation was not prescribed.
Study: NCT02698098

Intervention type: DRUG
Intervention: Methadone
Study: NCT02796755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Study participants randomized to this arm will take 100 mg/day of riluzole for 8 weeks.